2023
Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.
Naqvi S, He H, Siddiqi R, Khan N, Khakwani K, Ayaz A, Singh P, Ho T, Bryce A, McGregor B, Xu W, Bin Riaz I. Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis. Journal Of Clinical Oncology 2023, 41: 695-695. DOI: 10.1200/jco.2023.41.6_suppl.695.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMixed treatment comparisonGraphical user interfaceTreatment comparisonsRule-based algorithmSystematic reviewUser interfaceSignificant PFS benefitAdditional survival benefitFirst-line treatmentCertainty of evidenceEfficacious treatment optionRenal cell carcinomaBayesian networkSignificant differencesQuality of lifeAutomated fashionRisk of toxicityEvidence synthesis frameworkImmunotherapy combinationsMRCC patientsOS benefitPFS benefitSynthesis frameworkTreatment toxicity
2021
Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis.
Riaz I, Siddiqi R, Islam M, He H, Riaz A, Asghar N, Naqvi S, Warner J, Murad M, Kohli M. Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma: A Concluded Living Systematic Review and Meta-Analysis. JCO Clinical Cancer Informatics 2021, 5: 588-599. PMID: 34043431, DOI: 10.1200/cci.21.00035.Peer-Reviewed Original ResearchConceptsAdjuvant tyrosine kinase inhibitorsTyrosine kinase inhibitorsRenal cell carcinomaTrial sequential analysisCell carcinomaTKI monotherapyClinical trialsHigh-risk renal cell carcinomaMultiple large clinical trialsKinase inhibitorsLiving Systematic ReviewRandomized phase 2High-risk patientsCertainty of evidenceLarge clinical trialsKey clinical outcomesAdverse event riskLack of benefitOS benefitPROTECT trialGRADE approachClinical outcomesRandomized trialsCancer recurrenceSTUDY SELECTION